This clinical trial focuses on Eosinophilic Esophagitis (EoE), a chronic inflammatory condition that affects the esophagus (the tube that connects the mouth to the stomach). The study will test a medication called Solrikitug, which is given through subcutaneous injection (an injection under the skin), comparing it with a placebo to determine how well it works in treating inflammation and swallowing difficulties in adults with this condition.
The study consists of two parts. In the first part, participants will receive either Solrikitug or a placebo to evaluate how effectively the medication reduces inflammation in the esophagus and improves swallowing problems. The second part of the study will focus on understanding the long-term safety of the medication. Throughout the study, participants will receive regular medical check-ups and various tests to monitor their condition.
During the trial, participants may receive up to 500 milligrams of Solrikitug per day. The medication will be provided as a powder for injection that will be prepared before use. The study team will monitor participants for any side effects and evaluate how well the treatment works by examining tissue samples from the esophagus and tracking improvement in swallowing ability.
Belgium 
Italy 
Poland 
Spain 
The Netherlands 
